Which incentive is commonly granted for orphan drugs?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

Which incentive is commonly granted for orphan drugs?

Orphan drugs are drugs developed for rare diseases, and policy makers provide incentives to encourage this often-risky, low-volume research. The most common and impactful incentive is market exclusivity: a defined period after approval during which no other company can seek approval for the same drug and indication. This protection helps the sponsor recoup development costs in a market with few patients. In the U.S., this exclusivity lasts seven years; in the EU, it’s typically ten years. While other benefits like tax credits or grants may accompany orphan designation, the hallmark incentive is exclusivity. Options such as mandatory price reductions or elimination of patent protection aren’t standard incentives, and while some programs offer faster reviews, that’s not the core incentive for orphan drugs.

Orphan drugs are drugs developed for rare diseases, and policy makers provide incentives to encourage this often-risky, low-volume research. The most common and impactful incentive is market exclusivity: a defined period after approval during which no other company can seek approval for the same drug and indication. This protection helps the sponsor recoup development costs in a market with few patients. In the U.S., this exclusivity lasts seven years; in the EU, it’s typically ten years. While other benefits like tax credits or grants may accompany orphan designation, the hallmark incentive is exclusivity. Options such as mandatory price reductions or elimination of patent protection aren’t standard incentives, and while some programs offer faster reviews, that’s not the core incentive for orphan drugs.

More practice questions